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Abstract: Transmission of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant
Staphylococcus pseudintermedius (MRSP) between people and pets, and their co-carriage,
are well-described. Potential exchange of antimicrobial resistance (AMR) genes amongst these
staphylococci was investigated in vitro through endogenous bacteriophage-mediated transduction.
Bacteriophages were UV-induced from seven donor isolates of canine (MRSP) and human (MRSA)
origin, containing tet(M), tet(K), fusB or fusC, and lysates filtered. Twenty-seven tetracycline-
and fusidic acid- (FA-) susceptible recipients were used in 122 donor-recipient combinations
(22 tetracycline, 100 FA) across 415 assays (115 tetracycline, 300 FA). Bacteriophage lysates were
incubated with recipients and presumed transductants quantified on antimicrobial-supplemented
agar plates. Tetracycline resistance transduction from MRSP and MRSA to methicillin-susceptible
S. pseudintermedius (MSSP) was confirmed by PCR in 15/115 assays. No FA-resistance transfer
occurred, confirmed by negative fusB/fusC PCR, but colonies resulting from FA assays had high MICs
(≥32 mg/L) and showed mutations in fusA, two at a novel position (F88L), nine at H457[Y/N/L].
Horizontal gene transfer of tetracycline-resistance confirms that resistance genes can be shared
between coagulase-positive staphylococci from different hosts. Cross-species AMR transmission
highlights the importance of good antimicrobial stewardship across humans and veterinary species
to support One Health.
Keywords: staphylococci; zoonosis; MRSA; bacteriophage; MRSP
1. Introduction
Transmission of multidrug-resistant (MDR) bacterial pathogens between humans and pets
contributes to the spread of antimicrobial resistance (AMR) and is facilitated by frequent close contact
and advanced veterinary care [1]. While the transfer of MDR bacteria between hosts can be mitigated
through screening and hygiene measures, transfer of resistance determinants between co-colonising
bacteria will follow microbial rules of gene exchange.
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Methicillin-resistant Staphylococcus aureus (MRSA) presents a significant burden to human
healthcare through poorer clinical outcomes and higher treatment costs compared with
methicillin-susceptible S. aureus (MSSA) [2,3]. MRSA is occasionally isolated from infections
in pets, typically after reverse zoonotic transmission [4]. More recently, though, its “canine
counterpart”, methicillin-resistant S. pseudintermedius (MRSP), has emerged as a highly drug-resistant,
zoonotic pathogen in veterinary clinics [5,6]. Although MRSP is primarily adapted to dogs,
it shares many microbiological, clinical and epidemiological characteristics with MRSA. Both are
coagulase-positive opportunistic pathogens with the ability to colonise mucosae and skin
asymptomatically. Simultaneous co-carriage of and infection with S. aureus and S. pseudintermedius
have been documented in humans and dogs [7–9].
The acquisition or loss of mobile genetic elements (MGEs) carrying AMR genes, including plasmids,
transposons and staphylococcal cassette chromosome mec (SCCmec) elements, can lead to phenotypic
changes in AMR profiles of staphylococci [10]. Horizontal gene transfer (HGT) of MGEs can occur
between individual bacteria by transformation, conjugation, or transduction [11]. In S. aureus, this is
thought to be primarily by bacteriophage-mediated generalised transduction [12]. Comparatively little
information exists for S. pseudintermedius [13], but transduction seems the most likely mechanism for
HGT amongst co-colonising isolates. Integrated bacteriophages (prophages) have been identified in
S. pseudintermedius chromosomes while the tra gene complex, required for conjugation, was not found
in 15 sequenced isolates [14,15]. Transformation, which does not require cell-to-cell contact, appears to
occur rarely in S. aureus under natural conditions [12].
Bacteriophage-mediated generalised transduction relies on the presence of bacteriophage receptors
in recipient bacteria and is further dependent on the ability of MGEs to replicate or integrate
into the new host’s genome. HGT is controlled by Restriction-Modification (RM) systems and,
more rarely in staphylococci, by clusters of randomly interspersed short palindromic repeats (CRISPR)
systems, which protect bacteria from acquiring foreign DNA [12]. The distribution of RM variants
is lineage-associated in both S. aureus [16] and S. pseudintermedius [15], resulting in different MGEs
circulating within distinct S. aureus or S. pseudintermedius lineages.
Evidence for endogenous inter-species HGT of resistance determinants in staphylococci is
currently limited to transfer from coagulase-negative species (CoNS) or enterococci to S. aureus [17,18].
Phenotypic resistance to gentamicin, tetracycline and erythromycin has previously been transferred
in vitro and on mouse skin from S. hominis and S. epidermidis into S. aureus (both human- and
canine-derived) [17]. Moreover, the large MGE SCCmec, responsible for broad β-lactam resistance in
MRSA and MRSP, is thought to have been transferred from CoNS [19,20]. The rapid accumulation of
multiple resistance genes in MRSP suggests a less restrained acquisition of genetic material. In vivo,
unexpectedly high transfer rates of MGEs, containing genes related to host-adaptation, have been
observed in co-colonising S. aureus [21]. This is thought to be resulting from stress-linked generalised
transduction [21].
Almost all clinically relevant antimicrobial classes in human medicine are also authorised
and used globally in small animal veterinary practice [22,23]. One of the antimicrobial agents
reserved for the treatment of serious infections caused by MRSA in humans is fusidic acid (FA)
which is also widely used topically in dogs for the treatment of ear, eye and skin infections [24].
“Low-level” (Minimum Inhibitory Concentration [MIC] 4–16 mg/L) FA resistance in both S. aureus
and S. pseudintermedius has been associated with fusB or fusC [25,26]. These genes have been
primarily described on transposon- or SCCmec-like elements, found within plasmids, staphylococcal
pathogenicity islands (SaPIs), or being chromosomally integrated [25,26]. Whether these MGEs can
transfer between S. aureus and S. pseudintermedius remains to be answered. High-level resistance
to FA (MIC ≥ 64 mg/L) has been linked to chromosomal mutations (in fusA and/or fusE in small
colony variants) [25]. Another antimicrobial agent of importance in human and veterinary medicine is
tetracycline, a broad-spectrum agent classified by the WHO as “highly important” for humans [22]
and widely used for the treatment of respiratory tract infections in animals [27]. However, the wide
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distribution of tetracycline resistance genes, and their location on transposons (e.g., Tn916) and
plasmids [28], suggests a propensity for HGT, evidence for which has yet to be shown.
In this study, we demonstrate HGT of resistance genes between isolates of S. aureus and
S. pseudintermedius using assays to detect transduction mediated by induction of natural bacteriophages.
2. Materials and Methods
2.1. Bacterial Isolates
A total of seven donor and 27 recipient bacterial isolates were used from a frozen archive (−20 ◦C
in brain heart infusion broth (BHIB; Oxoid, Basingstoke, UK) and 20% glycerol (Fisher Scientific,
Loughborough, UK) (Table 1). Selection criteria were their tetracycline and FA resistance phenotypes
(disk diffusion for tetracycline, MICs for FA), genotypes, and their isolation sites, to span human,
canine, infection and carriage origins and a range of sequence types (STs). All S. pseudintermedius
isolates were collected from clinical submissions, representing the circulating lineages at the time
(2007 [n = 1], 2010–2016 [n = 20]). MRSA isolates (CC8 and CC22) represented two clonal complexes
found worldwide [29]. Species and respective resistances were confirmed by PCR following previously
described methods [30,31] for species-specific thermonuclease (nuc), methicillin-resistance (mecA),
and presence or absence of tet(M), tet(K), fusB, and fusC.
Donor isolates for tetracycline assays comprised one well-characterised MRSA of human infection
origin (COL), carrying tet(K) on plasmid pT181, and one fully sequenced, prophage-positive canine
infection MRSP (1726) with tet(M) on Tn916 [15]. Donor isolates for FA experiments included two
fusB-positive and three fusC-positive MRSP, with resistance genes most likely on transposon-like
elements in plasmids (fusB) or integrated into the chromosomal DNA in a SCCmec-like cassette (fusC).
Selection of FA-resistant donors was limited by the infrequent description of these genes in this
species [30]; FA-resistant S. aureus donors were not available for inclusion at the time. Recipient bacteria
representing different origins and STs were chosen; all were screened on brain heart infusion agar
(BHIA; Oxoid) containing either 30 mg/L tetracycline or 16 mg/L FA to confirm phenotypic susceptibility.
Two RM-deficient S. aureus laboratory strains were included as hyper-receptive recipient isolates [18].
To investigate the acquisition of tetracycline resistance, 22 different combinations of two donors
and 14 recipients, including the combination of MRSA COL and RM-deficient S. aureus RN4220 were
used; for FA assays, 100 combinations of five donors and 20 recipients were performed (Table 1). Initially,
all transduction assays were performed in triplicate, but for successful combinations (confirmed by
PCR for resistance gene in putative transductants), a further seven experiments (total ten replicates)
were performed.
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Table 1. Results from transduction assays using two tetracycline- and five fusidic acid-resistant bacterial donors (MRSA and MRSP), and 27 MR- and MS- S. aureus
and S. pseudintermedius recipients. Numbers represent transduction assays with the growth of more than two-fold higher bacterial colonies than negative control
plates, compared to the number of replicate attempts. For tetracycline resistance, confirmation of successful transduction was made by PCR. For fusidic acid assays,
all putative transductant colonies were subsequently shown not to carry fusB or fusC; mutations in fusA were identified by sequencing.
Donor









COL 1726 P0983 P1067 V1061 V1100 P1248




221833 ST263 1/10 3/10
Not Done
287735 ST82 0/3 1/10
289869 ST54 0/3 0/3
289595 ST1903 1/10 4/10
289589 ST1907 0/3 0/3
289418 ST1905 1/10 0/3
289385 ST1906 0/3 0/3
V1273 ST1085
Not Done
0/3 0/3 0/3 0/3 0/3
V0451 ST1091 0/3 0/3 0/3 1/3 0/3
V0806 ST54 0/3 0/3 0/3 0/3 0/3
P1361 ST1086 0/3 0/3 0/3 0/3 0/3
P1351 ST21 0/3 0/3 0/3 0/3 0/3
P1356 ST1092 0/3 0/3 0/3 0/3 0/3
251648 ST71 0/3 0/3 1/3 0/3 0/3





0/3 1/3 0/3 1/3 0/3 1/3
B021 CC15 (ST15) 0/3 0/3 0/3 0/3 0/3 0/3
B027 CC15 (ST15) 0/3 0/3 0/3 0/3 0/3 0/3
MRSA: methicillin-resistant S. aureus; MRSP: methicillin-resistant S. pseudintermedius; MSSP: methicillin-susceptible S. pseudintermedius; MSSA: methicillin-susceptible S. aureus.















0/3 0/3 0/3 0/3 0/3 0/3
MRSA
(Human Infection)
JE2 CC8 (ST8) 0/3 0/3 1/3 0/3 1/3 1/3
J220 CC8 (ST239)
Not done
0/3 0/3 1/3 2/3 0/3
J225 CC8 (ST239) 1/3 0/3 1/3 0/3 0/3
FPR3757 CC8 (ST8) 2/3 0/3 0/3 0/3 0/3
MRSA
(Human Carriage)
19B CC22 0/3 0/3 0/3 0/3 0/3 0/3
TW20 CC8 (ST239)
Not done




COL CC8 (ST250) 0/3 0/3 0/3 0/3 0/3
Total number transduction assays per antimicrobial 115 300
Total plates with increased growth
/total number of transduction assays 7/52 8/63 4/60 1/60 6/60 5/60 2/60
MRSA: methicillin-resistant S. aureus; MRSP: methicillin-resistant S. pseudintermedius; MSSP: methicillin-susceptible S. pseudintermedius; MSSA: methicillin-susceptible S. aureus.
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2.2. Induction of Bacteriophage
Overnight colonies from pure culture were grown in BHIB at 37 ◦C with shaking for 3 h; 1 mL
aliquots were centrifuged (3000 × g, 3 min), and supernatant discarded. Cell pellets were resuspended
in 7 mL bacteriophage buffer (0.1% 1M MgSO4, 0.4% CaCl2, 5% 1M Tris-HCl pH 7.8, 0.59% NaCl,
0.1% gelatin; Sigma-Aldrich Ltd., Gillingham, UK) and transferred to Petri dishes. The open Petri
dish was exposed to UV light (302 nm, UVP Dual-Intensity Transilluminator TM-20) for 20 s to induce
prophages [32,33]. Dish contents were added to 7 mL BHIB, incubated for 10 min at room temperature,
then for 2 h at 32 ◦C with gentle agitation, and finally overnight at room temperature to allow cell lysis.
Lysates were filtered (0.22 µm filter) and kept at 4 ◦C before being used for replicate experiments.
2.3. Bacteriophage Count
Recipient RN4220 colonies were incubated in 20 mL BHIB at 37 ◦C with shaking for 3 h.
Bacteriophage lysate was diluted in bacteriophage buffer (10−1 and 10−2); 100 µL of each was added
to 400 µL recipient cell broth and 30 µL 1M CaCl2 and incubated at room temperature for 15 min.
Dilutions were mixed with 7 mL bacteriophage top agar (bacteriophage buffer containing 2 mg/L
agar), poured over bacteriophage bottom agar plates (10 mg/L agar) and incubated at 32 ◦C for 24 h.
Number of lysis plaques within the bacterial lawn were counted, with one plaque representing one
phage particle.
2.4. Bacteriophage Transduction
Recipient bacteria were incubated in 20 mL LK broth (LKB; Luria broth with KCl instead of NaCl;
1% tryptone, 0.5% yeast extract, 0.7% KCl; Sigma-Aldrich Ltd., Gillingham, UK) at 37 ◦C overnight with
shaking. Broth was centrifuged (4000× g, 10 min), supernatant discarded, and cell pellets resuspended
in 1 mL LKB. In total, 100 µL of the recipient cell suspension, 100 µL bacteriophage lysate, and 200 µL
LKB along with 2 µL CaCl2 (Sigma-Aldrich Ltd., Gillingham, UK; to a final concentration of 8 mM)
were incubated at 37 ◦C for 45 min with shaking. Subsequently, 200 µL ice-cold 0.02 M sodium citrate
was added (Honeywell International Inc., Bucharest, Romania) to chelate calcium and prevent further
phage binding and cell lysis. Cell suspensions were centrifuged (3000× g, 3 min), supernatant discarded,
the pellet resuspended in 200 µL ice-cold sodium citrate, and left for 2 h on ice [33].
The 200 µL solutions were spread using hockey-stick spreaders onto the surface of an LK bottom
agar plate (10 g/L agar) containing sub-inhibitory antimicrobial concentrations to induce resistance gene
expression (0.3 mg/L tetracycline or 0.03 mg/L FA) and incubated at 37 ◦C for 45 min. Four-to-five mL of
LK top agar (2 g/L agar) containing inhibitory antimicrobial concentrations (30 mg/L tetracycline in total
or 16 mg/L FA in total) were overlaid, plates incubated upright for 48 h at 37 ◦C, and colonies counted.
A negative control with 100 µL LKB in place of bacteriophage lysate was included for every
combination and growth compared to transduction plates. Colony numbers at least twice those seen on
the corresponding negative control were deemed significant growth, indicative of resistance transfer.
2.5. Confirmation of Suspected Transductants
From each assay with significant growth, 2–9 putative transductant colonies were subcultured
onto BHIA containing either 30 mg/L tetracycline or 16 mg/L FA to confirm phenotypic susceptibility;
expected species and the presence/absence of respective resistance genes were again investigated [30,31].
For isolates grown on FA-supplemented agar but negative for fusB and fusC, MICs were determined
for at least two colonies, as well as for their respective donor and recipient [30]. In 1 to 3 representative
fusB/fusC negative post-transduction colonies from each recipient with MICs ≥ 32 mg/L, fusA was
amplified and sequenced alongside that of their original recipient following a previously described
method [30].
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2.6. Statistical Analyses
In IBM SPSS Statistics version 26 (significance p < 0.05), transduction rates (transductants/mL)
and frequencies were compared by Kruskal-Wallis tests with the Dunn-Bonferroni post hoc method.
3. Results
3.1. Bacteriophage Count
Bacteriophage count could not be established as the RN4220 bacterial lawn did not show any lytic
plaques for phage lysate from any donor; transducing phage counts have been shown previously not
to correlate with lytic phage counts [33].
3.2. Transduction of Tetracycline Resistance
To study HGT of tetracycline resistance, bacteriophage lysates from one tet(M)-positive
and one tet(K)-positive donor were cultured with 14 tetracycline-susceptible recipients.
Phenotypically tetracycline-resistant colonies grew from seven of the 22 different donor/recipient
combinations (initially done in triplicate) (Table 1); expected nuc and acquisition of tet(M) or tet(K)
were confirmed in all. Transfer occurred from MRSA COL into control MSSA RN4220 and three
methicillin-susceptible S. pseudintermedius (MSSP) recipients, and from MRSP 1726 into three MSSP
recipients (Figure 1). In contrast, no transduction of phenotypic tetracycline resistance was seen from
MRSP into S. aureus (including both RM-deficient recipients). Including the subsequent additional
seven replicates from successful pairings (115 assays in total), transduction occurred in 15/115 assays,
confirmed by PCR in all 38 tested colonies. Reproducibility was low in most replicate experiments with
a maximum of 4/10 positive repeats found from MRSA COL into RN4220 and from MRSP into an MSSP.
Growth of <10 colonies per plate (Figure 1) was seen on 9/23 negative controls, representing seven
recipients (6 MSSP, 1 MSSA). There was no difference (P = 0.994) between colony counts/mL for
transduction between MRSP-MSSP, MRSA-MSSP or MRSA-RM-deficient MSSA (Table 2).Microorganisms 2020, 8, x FOR PEER REVIEW 9 of 12 
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Figure 1. Recipient MSSP 287735 growth after transduction assays (A) on agar containing 30 mg/L 
tetracycline with phage lysate from MRSP 1726 (tet(M) donor); (B) on agar containing 30 mg/L 
tetracycline control with no phage lysate; (C) on agar containing 16 mg/L fusidic acid with no phage 
lysate. Note the breakthrough growth on plate C (colony count n = 41). Smaller colonies are those 
embedded in the agar. 
3.3. Transduction of FA Resistance 
For FA resistance, bacteriophage lysate from two fusB- and three fusC-positive MRSP donors 
was combined with 20 FA-susceptible recipients (Table 1). Of the 300 transduction plates in total, 18 
showed significant growth. Growth of up to 50 colonies was seen on 24/35 negative control plates 
from all but three (P1361, V1273, B021) recipients. Neither fusB nor fusC were detected in the 59 
colonies tested post-transduction. Significant growth was seen more frequently on transduction 
assays for MRSA recipients (13/120 plates) than for MSSP recipients (2/120 plates; P = 0.032); the 
frequency of growth was similar for the 60 MSSA assays. 
All tested colonies from FA transduction assays (two from each plate) had MICs higher than 
their donor (donors 4 mg/L–16 mg/L; putative transductants 32 mg/L–>64 mg/L) and their recipient 
isolates (0.03 mg/L–0.06 mg/L). Sequencing of fusA in 11/11 post-transduction assay colonies 
identified mutations in one of two amino acid positions (Table 3). The most common mutation (9/11 
colonies) was in amino acid 457 (H457Y, H457N, H457L); two colonies had the mutation F88L, located 
in domain I of fusA. 
Table 3. Fusidic acid minimum inhibitory concentrations (MIC) and mutations in fusA (including the 
novel position F88L) after exposure of MRSA, MSSA, and MSSP to subinhibitory concentrations of 
fusidic acid. PCR confirmed species and methicillin-resistance as the same as the original recipient 
isolate. 







MSSP 251648 (0.06) 32 H457Y CAC → TAC 
MSSA B019 (0.06) 
32 H457Y CAC → TAC 
32 F88L TTC → CTC 
MRSA 
TW20 (0.06) 32 F88L TTC → TTA 
J220 (0.06) 
>64 H457N CAC → AAC 
32 H457Y CAC → TAC 
J225 (0.06) 
32 H457Y CAC → TAC 
64 H457N CAC → AAC 
64 H457N CAC → AAC 
FPR3757 (0.06) 64 H457L CAC → CTC 
JE2 (0.06) 32 H457Y CAC → TAC 
MSSP: methicillin-susceptible S. pseudintermedius; MSSA: methicillin-susceptible S. aureus; MRSA: 
methicillin-resistant S. aureus.
Figure 1. Recipient MSSP 287735 growth after transduction assays (A) on agar containing 30 mg/L
tetracycline with phage lysate from MRSP 1726 (tet(M) donor); (B) on agar containing 30 mg/L
tetracycline control with no phage lysate; (C) on agar containing 16 mg/L fusidic acid with no phage
lysate. Note the breakthrough growth on plate C (colony count n = 41). Smaller colonies are those
embedded in the agar.
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Table 2. Number of transductant cells/mL following successful transduction assays for tet(M) and
tet(K). Cell numbers are derived from colony counts following transduction assays incubated at 37 ◦C
for 48 h on LK agar containing 30 mg/L tetracycline.




Transductant Cells/mLBacterial Type Isolate TetracyclineResistance Gene Bacterial Type Isolate
MRSP 1726 tet(M) MSSP
221833 3/10 1105 (250–1510)
287735 1/10 1535
289595 4/10 92.5 (25–160)




RM-def MSSA RN4220 4/10 62.5 (25–995)
MRSA: methicillin-resistant S. aureus; MRSP: methicillin-resistant S. pseudintermedius; MSSP: methicillin-susceptible
S. pseudintermedius; RM-def MSSA: restriction-modification system deficient methicillin-susceptible S. aureus.
3.3. Transduction of FA Resistance
For FA resistance, bacteriophage lysate from two fusB- and three fusC-positive MRSP donors was
combined with 20 FA-susceptible recipients (Table 1). Of the 300 transduction plates in total, 18 showed
significant growth. Growth of up to 50 colonies was seen on 24/35 negative control plates from all but
three (P1361, V1273, B021) recipients. Neither fusB nor fusC were detected in the 59 colonies tested
post-transduction. Significant growth was seen more frequently on transduction assays for MRSA
recipients (13/120 plates) than for MSSP recipients (2/120 plates; P = 0.032); the frequency of growth
was similar for the 60 MSSA assays.
All tested colonies from FA transduction assays (two from each plate) had MICs higher than
their donor (donors 4 mg/L–16 mg/L; putative transductants 32 mg/L–>64 mg/L) and their recipient
isolates (0.03 mg/L–0.06 mg/L). Sequencing of fusA in 11/11 post-transduction assay colonies identified
mutations in one of two amino acid positions (Table 3). The most common mutation (9/11 colonies)
was in amino acid 457 (H457Y, H457N, H457L); two colonies had the mutation F88L, located in domain
I of fusA.
Table 3. Fusidic acid minimum inhibitory concentrations (MIC) and mutations in fusA (including the
novel position F88L) after exposure of MRSA, MSSA, and MSSP to subinhibitory concentrations of fusidic
acid. PCR confirmed species and methicillin-resistance as the same as the original recipient isolate.





MSSP 251648 (0.06) 32 H457Y CAC→ TAC
MSSA B019 (0.06)
32 H457Y CAC→ TAC
32 F88L TTC→ CTC
MRSA
TW20 (0.06) 32 F88L TTC→ TTA
J220 (0.06) >64 H457N CAC→ AAC
32 H457Y CAC→ TAC
J225 (0.06)
32 H457Y CAC→ TAC
64 H457N CAC→ AAC
64 H457N CAC→ AAC
FPR3757 (0.06) 64 H457L CAC→ CTC
JE2 (0.06) 32 H457Y CAC→ TAC
MSSP: methicillin-susceptible S. pseudintermedius; MSSA: methicillin-susceptible S. aureus; MRSA:
methicillin-resistant S. aureus.
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4. Discussion
For the first time, our results provide phenotypic and molecular evidence for AMR transfer
between different coagulase-positive staphylococcal species from human and canine origin, mediated by
endogenous bacteriophages.
This cross-species spread of AMR, from the human pathogen S. aureus into the canine pathogen
S. pseudintermedius, is of particular relevance to the often-close contact settings between pet owners
and their pets, with S. aureus acting as a potential reservoir of resistance genes for S. pseudintermedius.
It draws new attention to a potential risk to pets from contact with humans. This adds to a
wealth of information focusing on the irrefutable priority direction of pet-to-human transfer [34].
Dogs and humans may be at least transient carriers (and co-carriers) of staphylococcal species
adapted to the respective “other” primary host [4,5]. Our results add an extra layer of complexity
to the potential clinical implications of close companionship with our pets, should HGT occur from
S. aureus to S. pseudintermedius in vivo. Why no transduction of tetracycline resistance genes occurred
from MRSP into S. aureus (including RN4220) remains unclear, but may include more efficient
RM-systems, CRISPRs (although rarely described in staphylococci), a lack of bacteriophage receptors
in S. aureus, plasmid incompatibility, or non-compatible RM systems (which may or may not be lineage
specific) [12,14,16]. Similar unilateral transfer preferences were previously noted in an earlier study
using exogenous bacteriophages in other staphylococcal species [35], although HGT was observed
bidirectionally between S. aureus and S. pseudintermedius.
The low reproducibility of transduction of tetracycline resistance genes in successful pairings was
surprising. It may have been due to low concentrations of endogenous transducing bacteriophages in
lysates, or low copy number of tet(M)/tet(K) within induced bacteriophages. While this may suggest
that cross-species gene exchange represents only a minor contribution to the overall spread of AMR,
our findings prove a new concept in the evolution of MDR pathogens, in an area directly impacting on
human health. Furthermore, transduction rates are difficult to compare as the number of successful
replicates are rarely stated (instead described as variation (mean ± SD)). Our transduction rates in
successful replicates (number of transductant cells/mL) were similar to those described previously
using UV-light induction of bacteriophages (approximately 10–350 cfu/mL previously c.f. 25–1535 in
this study; Table 2) [33]. Two MSSP recipients (221833 and 287735) had particularly high transductant
cell counts, suggesting they may have weaker transfer barriers or greater phage receptor expression,
allowing a higher transduction rate. This is also indicated by the acceptance of DNA by recipients
221833 and 289595 in more replicate experiments, from both MRSA and MRSP donors. It is possible that
transfer of resistance genes via transformation of DNA present in lysates could occur, however S. aureus
competence genes are poorly expressed by mutated sigma factors and post-transcriptional control,
resulting in extremely rare transfer frequency [12,36]. The reasons why the phage lysate did not
form plaques in the RN4220 bacterial lawn are unclear. Potentially this could be due to missing or
modified phage receptors in this strain, or the induction of a novel transducing phage. It is possible
that despite being RM-deficient to our current knowledge, RN4220 may contain other undiscovered
types of phage immunity. This non-plaque-forming phenomenon with RN4220 is not uncommon
to see when plating transducing phages induced from clinical S. aureus isolates (unpublished data),
and it has been previously demonstrated that the presence of lytic phages does not correlate with
transducing phage [33]. However, it cannot be discounted that the apparent absence of FA resistance
gene transduction could be the result of a lack of transducing phage.
The risk of interspecies HGT may be greater in vivo than in the laboratory, as has been
demonstrated previously for other MGEs [17,21]. Plasmid-borne gentamicin resistance transfer
from the coagulase-negative S. epidermidis into S. aureus was 10-100-fold greater on mouse skin than
in broth filter experiments [17] and similarly, HGT of host-adaptation determinants on pig skin was
substantially higher compared to the same isolates co-incubated in vitro [21]. However, the reasons
underpinning why transfer is observed at a higher rate in vivo than in vitro are still largely unknown.
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It is thought that this may relate to environmental conditions that are not replicated in vitro, which may
trigger staphylococcal isolates to selectively amplify HGT.
The lack of transfer of fusB and fusC in this study is encouraging with regard to the preservation
of FA clinical efficacy in human and veterinary medicine. However, the finding needs to be interpreted
with caution. Firstly, the development of high-level resistance likely due to fusA mutations following
exposure to relatively low concentrations of FA is of concern, although fusA mutations are rarely
documented in clinical isolates [25,30]. This low prevalence of FA resistance, despite FA being widely
used in veterinary and human medicine for over 50 years, suggests that its use is not causing a ‘crisis’
of resistance. Indeed, in veterinary medicine FA is used as topical therapy where it exceeds typical
MICs for staphylococci by a significant order of magnitude [36]. Thus, it seems prudent to suggest
that proactive surveillance of resistance in both human- and veterinary-derived staphylococci would
suffice to monitor this situation. However, it does not indicate a current need to restrict the use of this
antimicrobial to humans only at this time. In this study, transduction may have also been hampered by
a lack of prophage in our donors, as reported for a small number of S. pseudintermedius lineages [14].
The mutations observed in fusA of S. pseudintermedius occurred in the same position as described in
S. aureus (amino acid 457), confirming the importance of this mutation in resistance development [25].
The role of the novel mutation (F88L) in conferring tolerance to FA should be further investigated.
In conclusion, the description of MGE transfer between S. aureus and S. pseudintermedius illustrates
ongoing genetic evolution amongst major zoonotic staphylococcal pathogens. Selective pressures
in one host may thus contribute to the evolution of more drug-resistant isolates adapted to another
host. Whilst the wider context of direction of transfer and the prioritisation of human over animal
health remain important considerations, there is clearly a need for response to the dissemination
of AMR within shared bacterial populations. Despite previous significant attention on the use of
antimicrobial agents in livestock, companion animal medicine is in some ways left lagging behind.
Efforts to develop and disseminate responsible antimicrobial use guidelines for companion animal
medicine need to continue, also to align interests in the sense of One Health. At present, though,
the well-documented benefit from pet ownership on human health likely markedly outweighs the risk
from zoonotic transmission and HGT in methicillin-resistant staphylococci [37].
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